Analysts Anticipate ESML Will Reach $43
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (Symbol: ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $43.23 per unit.
With ESML trading at a recent price near $38.80 per unit, that means that analysts see 11.42% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of ESML's underlying holdings with notable upside to their analyst target prices are Intellia Therapeutics Inc (Symbol: NTLA), Viridian Therapeutics Inc (Symbol: VRDN), and Arcturus Therapeutics Holdings Inc (Symbol: ARCT). Although NTLA has traded at a recent price of $32.12/share, the average analyst target is 125.51% higher at $72.43/share. Similarly, VRDN has 105.01% upside from the recent share price of $18.71 if the average analyst target price of $38.36/share is reached, and analysts on average are expecting ARCT to reach a target price of $62.43/share, which is 61.06% above the recent price of $38.76. Below is a twelve month price history chart comparing the stock performance of NTLA, VRDN, and ARCT:
Below is a summary table of the current analyst target prices discussed above:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| iShares ESG Aware MSCI USA Small-Cap ETF | ESML | $38.80 | $43.23 | 11.42% |
| Intellia Therapeutics Inc | NTLA | $32.12 | $72.43 | 125.51% |
| Viridian Therapeutics Inc | VRDN | $18.71 | $38.36 | 105.01% |
| Arcturus Therapeutics Holdings Inc | ARCT | $38.76 | $62.43 | 61.06% |
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
BGSF Options Chain
CHRD market cap history
Leidos Holdings Average Annual Return
